Day 5 Track 1

Research and Clinical Trials

Robert Coleman, MD, FACOG, FACS, Gynecologic Oncologist and Chief Scientific Officer, US Oncology Research

The Sarah Cannon Model: Evolutionary Approach to Research

David Spigel, MD, Chief Scientific Officer, Sarah Cannon Cancer Institute

Biosimilar Adoption in Oncology: How Attitudes Have Changed and What’s Ahead?

Sonia Oskouei, PharmD, BCMAS, DPLA, Vice President, Biosimilars, Cardinal Health

Use of biosimilars among oncologists has increased markedly over the past year, with some oncology biosimilars now capturing more market share than their originator products. This session will explore how oncologists’ attitudes about biosimilars and prescribing behaviors have shifted, what factors have led to those changes, and what barriers to adoption still exist for some physicians. The discussion will be based on original research conducted with community-based oncologists from 2017 through 2020.

Supporting Oncology Nurses in a World of Dynamic Medical Knowledge

Lance Ortega, MBA, BSN, RN, OCN, Director, Nursing Services, Texas Oncology

Gain effective practices for streamlining the onboarding process for new nurses by leveraging print materials, eLearning, and virtual education; standardizing nurse education across all clinic sites; and conducting productive virtual huddle meetings